



Sanofi Receives MOH Approval of Once-Daily Basal Insulin Toujeo®

– New basal insulin demonstrated glycemic control with less confirmed hypoglycemia –

Sanofi Egypt announced today that the Egyptian Ministry of Health & Population (MOH) approved Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with Type 1 & type 2 diabetes. Toujeo is expected to be available in Egypt at the mid of Feb 2018.

“Sanofi is proud of its long heritage in diabetes and insulin therapies, including Lantus® which has supported patients in the management of their diabetes for more than a decade. With the MOH approval of Toujeo, Sanofi builds on its strong legacy and looks forward to bringing a new treatment option to people living with diabetes.” said Hala Ramzy, Medical Head, Sanofi Egypt & Sudan.

Despite the proven efficacy of insulin, ensuring effective titration and maintenance can be a challenge for both patients and healthcare professionals due to hypoglycemia concerns. Toujeo provides a new option that may help patients manage their diabetes.

Toujeo will be available in the Toujeo SoloSTAR®, a disposable prefilled pen which contains 450 units of Toujeo.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

About Sanofi Egypt

Sanofi with its 1,200 employees has been working tirelessly in Egypt for more than 55 years, to ensure the availability of quality products and effective distribution

Sanofi in Egypt is among the top five leading pharmaceutical companies in Egypt, contributing to the Egyptian healthcare market creating economic value. Sanofi Egypt offers solutions for the Egyptian patients in many therapeutic areas providing a wide range of innovative treatment solutions in biotechnology, vaccines, diabetes, oncology, and cardiovascular diseases; multiple sclerosis, rare diseases and consumer health products.

Sanofi Industrial Affairs is one of the top 10 manufacturing plants in term of volume in Egypt.

Sanofi Egypt has been awarded as a country’s “Top Employer” in 2018 by “The Top Employers Institute,” which has been recognizing Human Resources excellence around the world for over 25 years.

Follow us On Twitter: @SanofiEG